To estimate the effect of women's representation in government on obstetric and contraceptive targets identified by the Millennium Development Goals (MDG). MDGs were implemented to address poverty, equality, education, and environmental sustainability. This evaluation was done to explore how improving women's parity in politics impacts achieving reproductive health outcomes. STUDY DESIGN: We used the MDG database (1990 to 2015) to estimate the effect of women in government (defined as % seats held by women in parliament) on three outcomes: births attended by skilled health personnel, current contraceptive use among married women, and maternal mortality. Evaluation was performed of all countries and individual countries of varying levels of development (United States, Uganda, Haiti, India, Mexico, and United Kingdom). SPSS was used for data analysis. Spearman's correlation was used to test the association. RESULTS: There is an inverse relationship between women in parliament and maternal mortality (all country Rho ¼ -0.26, p<0.0001; case studies Rho -0.7 to -0.9, p<0.001 to 0.001). However, women in parliament is proportional to both births attended by skilled health personnel (all country Rho ¼ 0.1, p ¼ 0.006; case studies Rho 0.7 to 1, p<0.0001 to 0.3) and contraceptive use (all country Rho ¼ 0.2, p<0.0001; case studies Rho -0.2 to 0.9, p 0.05 to 1). CONCLUSION: As the percentage of women in parliament increases, so do births attended by skilled health personnel and contraceptive use while maternal mortality decreases. This study indicates that a relationship exists between increasing women's participation in government and improvement in women's health outcomes.
OBJECTIVE: Preeclampsia in pregnancy is a leading cause of prematurity, and maternal and neonatal morbidity and mortality. Incidence has risen in part from trends in obesity and older age in pregnant women. Evidence of preeclampsia costs is scarce due to data challenges identifying preeclampsia cases and matching mothers and infants. This is the first study using primary data to provide U.S. case-based preeclampsia healthcare cost estimates for mothers and infants from a payer perspective, with comparisons to both normal and hypertensive pregnancies. STUDY DESIGN: Electronic health record and billing data from a large regional integrated healthcare system in Pennsylvania, Geisinger, were used to identify mother-singleton infant pairs with deliveries between 2010 and 2015. Data on their clinical care and costs using actual payment amounts were compiled for the following time periods: 20 weeks gestation to 6 weeks post-delivery for mothers and birth to 12 months for infants. Three pregnancy study cohorts (preeclampsia, normal and hypertension) were defined and matched using a 1:1:1 ratio on the basis of mother's age, parity, BMI and comorbidities. Costs per pregnancy were calculated in 2015 dollars and preeclampsia incremental costs estimated by subtracting the average cost of the matched cohorts. RESULTS: Final study population included 712 matched mother/infant pairs in each cohort. Results for preeclampsia cases' total incremental costs were $28,603 ($3,374 for mothers and $25,229 for infants) compared to normal and $17,608 ($1,358 and $16,250) compared to hypertension (Figure 1) . The mean cost per infant was dependent on gestational age, ranging from $214,941 at less than 28 weeks to $6,071 at full term. Mothers with preeclampsia had earlier deliveries with 36.5 median gestational weeks at birth compared to 38.7 for hypertension and 39.5 for normal (p<0.0001). A significantly larger percentage of preeclampsia mothers and infants (13.9% for mothers and 14.6% for infants) experienced adverse events compared to normal (4.1% and 0.7%) and hypertension (9.4% and 4.8%) (p<0.0001). CONCLUSION: The economic burden of preeclampsia healthcare costs is significant with the main cost drivers being infant healthcare costs associated with lower gestational age and greater adverse outcomes.
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